SEC Form 4 · accession 0001104659-17-048994
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francesco Maria Lavino
Officer — Chief Commercial Officer
Period of report
Jul 31, 2017
Accepted (ET)
Aug 2, 2017 · 6:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | — | Jul 31, 2017 | A | 150,000 | A | — | Jul 31, 2027 | Ordinary Shares | 150,000 | 150,000 | D |
Explanation of responses
- F1The exercise price is Euro 8.94 per share.
- F2This option was granted on July 31, 2017. Vesting will begin on July 31, 2017 and end on July 31, 2021. Twenty-five percent (25%) of the option will vest on July 31, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period.